THE INNOVATIVE MEDICINES INITIATIVE
The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients.
IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.
IMI 2 Open Info Day - registration open
Registration for the IMI 2 Open Info Day on 30 September in Brussels is now open.
Sign up to learn more about the IMI 2 rules and procedures as well as the first Call topics.
- 19/09/2014 : RT @UBIOPRED: Read part 2 of Martine's report on ERS Congress. http://t.co/tVef6k4uE3 #ubiopred #ERS2014
- 19/09/2014 : Great to see IMI’s #AntibioticResistance programme cited in a report to Barack Obama! http://t.co/0TXEWCSefa (p26)
- 18/09/2014 : RT @eupatients: How @eupati is helping patients understand their medicines Article in the Synergist http://t.co/BoTR1ewHKu